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Abstract
HIV protease inhibitors must penetrate into cells to exert their action. Differences in the intracellular pharmacokinetics of
these drugs may explain why some patients fail on therapy or suffer from drug toxicity. Yet, there is no information available
on the intracellular levels of HIV protease inhibitors in HIV infected children, which is in part due to the large amount of
sample that is normally required to measure the intracellular concentrations of these drugs. Therefore, we developed an
ultra-fast and sensitive assay to measure the intracellular concentrations of HIV protease inhibitors in small amounts of
peripheral blood mononuclear cells (PBMCs), and determined the intracellular concentrations of lopinavir and ritonavir in
HIV infected children. An assay based on matrix-assisted laser desorption/ionization (MALDI) - triple quadrupole mass
spectrometry was developed to determine the concentrations of HIV protease inhibitors in 10 mL plasma and 16106 PBMCs.
Precisions and accuracies were within the values set by the FDA for bioanalytical method validation. Lopinavir and ritonavir
did not accumulate in PBMCs of HIV infected children. In addition, the intracellular concentrations of lopinavir and ritonavir
correlated poorly to the plasma concentrations of these drugs. MALDI-triple quadrupole mass spectrometry is a new tool for
ultra-fast and sensitive determination of drug concentrations which can be used, for example, to assess the intracellular
pharmacokinetics of HIV protease inhibitors in HIV infected children.
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Introduction
HIV protease inhibitors exert their action inside cells that are
susceptible to HIV infection. The intracellular pharmacokinetics of
these drugs, its relation to the plasma pharmacokinetics, and its
relation to drug efficacy and toxicity is therefore an active area of
research [1–10]. However, determination of the intracellular levels
of antiretroviral drugs is an analytical challenge, because of the
small amount of target cells, e.g. peripheral blood mononuclear cells
(PBMCs), which can be obtained from a patient’s blood sample.
Approximately one million PBMCs can be obtained from 1–2 mL
blood. This amount of PBMCs has a total intracellular volume of
,0.4 mL, while 500 – 1000 mL plasma can be obtained from that
same blood sample. As a consequence, much is known about the
plasma pharmacokinetics of HIV protease inhibitors in HIV
infected children, but no information is available on the intracellular
levels of HIV protease inhibitors in this group of patients [11–14].
Here, we describe a new assay for fast and sensitive
determination of HIV protease inhibitor levels in one million
PBMCs and 10 mL plasma, and its application in HIV infected
children treated with Kaletra, a co-formulation of the HIV
protease inhibitors lopinavir and ritonavir. To this end we used the
novel matrix-assisted laser desorption/ionization (MALDI) – triple
quadrupole mass spectrometry technique [15–23].
Materials and Methods
Ethics Statement
This research has been approved by the Medisch Ethische
Toetsings Commissie of the Erasmus MC (#206.382/2001/238).
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Written informed consent was obtained from the patients’ parents
or legal guardians.
Chemicals and solvents
Methotrexate (Emthexate PF for parenteral administration,
PharmaChemie BV, Haarlem, the Netherlands), saquinavir
(donated by F.Hoffmann La-Roche, Basel, Switzerland), indinavir
(donated by Merck, Rahway, NJ, USA), nelfinavir (donated by
Pfizer, Groton, CT, USA), lopinavir and ritonavir (donated by
Abbott Laboratories, Illinois, IL, USA), Kaletra oral solution
(80 mg/mL lopinavir and 20 mg/mL ritonavir; Abbott; obtained
from dept. Pharmacy, Erasmus MC, Rotterdam, the Netherlands),
nevirapine and tipranavir (donated by Boehringer Ingelheim,
Ingelheim am Rhein, Germany), efavirenz (Moravek, Brea, CA,
USA), metronidazole, metoprolol, piroxicam, amoxicillin, and
carbamazepine (all from Sigma-Aldrich, Zwijndrecht, the Nether-
lands). a-cyano-4-hydroxycinnamic acid solution (Agilent Tech-
nologies; 6.2 mg/mL in methanol/acetonitrile/water 36/56/8 v/
v/v, pH=2.5). Sodium iodide (purity .99.99%, Sigma-Aldrich,
Zwijndrecht, the Netherlands). Methanol (ULC/MS grade,
Biosolve, Valkenswaard, the Netherlands). Phosphate-Buffered
Saline (PBS; 1x; pH=7.4; CaCl2 and MgCl2; product number
10010) was obtained from Invitrogen. Red blood cell lysis buffer
was obtained from Roche Diagnostics (Mannheim, Germany, Cat.
No. 11814389001).
Stock solutions
All stock solutions for MALDI-triple quadrupole MS analysis
were prepared in methanol by serial dilution. As internal standards
we used: 20 mM nelfinavir (quantitation of lopinavir and ritonavir
in plasma), 5 mM methotrexate (quantitation of saquinavir,
nelfinavir, and indinavir in plasma), 2 mM nelfinavir (quantitation
of lopinavir and ritonavir in 16106 PBMCs). To investigate the
effect of co-medication on the quantitation performance, the
following drug mixtures were added to the quality control samples:
drug mixture A: 10 mM carbamazepine, metoprolol, metronida-
zole, amoxicillin, piroxicam, nevirapine, saquinavir, efavirenz,
indinavir, and tipranavir (quantitation of lopinavir and ritonavir in
plasma). Drug mixture B: 10 mM carbamazepine, metoprolol,
metronidazole, amoxicillin, piroxicam, nevirapine, lopinavir,
efavirenz, ritonavir, and tipranavir (quantitation of saquinavir,
indinavir, and nelfinavir in plasma).
Matrix preparation
For simultaneous quantitation of lopinavir and ritonavir, 10 mL
100 mM NaI in MeOH was added to 990 mL matrix solution (a-
cyano-4-hydroxycinnamic acid). For simultaneous quantitation of
saquinavir, indinavir, and nelfinavir, the matrix solution was
diluted 1:1 v/v in nanopure water.
MALDI-triple quadrupole mass spectrometry
A FlashQuant Workstation equipped with a 4000 QTRAP mass
analyzer (MDS Analytical Technologies, Concord, Ontario,
Canada) was used for automated measurements of the samples.
The spots were measured in the selected reaction monitoring
mode (unit resolution) by moving the target plate in a straight
horizontal line at a speed of 1 mm per second while firing of the
laser at 1,000 Hz, which corresponds to an analysis time of 4.5
seconds per spot. For specific setting see Table 1. Analyst 1.4.2.
and FlashQuant 1.0 software (MDS Analytical Technologies,
Concord, Ontario, Canada) were used to operate the instrument
and for automated data analysis. A calibration curve was
constructed by plotting the analyte-to-internal standard area ratios
against the concentrations spiked using a 1/concentration2
weighed linear curve. Quality controls were used to check the
validity of the calibration curves. The absolute lower limit of
quantification was set at the mean analyte area in the zero samples
+10 times the standard deviation. Samples were spotted onto Opti-
TOF 384 well stainless steel target plates (123681 mm; MDS
Analytical Technologies, Concord, Ontario, Canada).
Plasma sample preparation for MALDI-triple quadrupole
MS
Plasma samples were prepared in 1.5 mL Eppendorf safe-lock
tubes: 10 mL plasma were added to methanol, mixed using a
pipette, and spiked with internal standard, analytes, and additional
drugs, depending on the type of sample. Calibrators: 70 mL
MeOH +10 mL plasma +10 mL internal standard +10 mL analytes.
Quality controls: 60 mL MeOH +10 mL plasma +10 mL internal
standard +10 mL analytes +10 mL drug mixture. Unknowns:
80 mL MeOH +10 mL plasma +10 mL internal standard. Blank:
90 mL MeOH +10 mL plasma. Zero: 70 mL MeOH +10 mL
plasma +10 mL internal standard +10 mL drug mixture. For
quantitation of lopinavir and ritonavir, nelfinavir (20 mM solution)
was used as internal standard. For quantitation of saquinavir,
indinavir, and nelfinavir, methotrexate (5 mM solution) was used
as internal standard. To the quality control samples for lopinavir
and ritonavir quantitation, drug mixture ‘‘A’’ was spiked
containing carbamazepine, metoprolol, metronidazole, amoxicil-
lin, piroxicam, nevirapine, saquinavir, efavirenz, indinavir, and
tipranavir (10 mM each). To the quality control samples for
saquinavir, indinavir, and nelfinavir, drug mixture ‘‘B’’ was spiked
Table 1. Instrument settings for quantitative analysis of HIV protease inhibitors.
compound form ion transition CE (V) CXP (V) plate (V) laser power (%)
lopinavir sodiated 651.4 R 439.3 52 10 60 40
ritonavir sodiated 743.3 R 573.3 50 10 60 40
nelfinavir sodiated 590.4 R 338.2 50 10 60 40
saquinavir protonated 671.4 R 570.4 44 8 65 35
indinavir protonated 614.4 R 421.2 44 12 50 35
nelfinavir protonated 568.4 R 330.2 45 8 50 35
methotrexate protonated 455.2 R 308.2 30 8 50 35
The skimmer was set at 0 V, CAD gas at 6, source gas at 10. CE = collision energy. CXP = collision cell exit potential. Plate = target plate containing the samples. Dwell
time for each ion transition was 10 ms.
doi:10.1371/journal.pone.0011409.t001
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containing carbamazepine, metoprolol, metronidazole, amoxicil-
lin, piroxicam, nevirapine, lopinavir, efavirenz, ritonavir, and
tipranavir (10 mM each). Samples were extracted for at least one
hour at 5uC and were then centrifuged at 14,000 rpm at room
temperature for 5 minutes. Subsequently, supernatants were
mixed with matrix solution (1:2, v/v; for matrix see Section
‘‘matrix preparation’’), 0.75 mL matrix/sample mixture was
deposited on three positions on the target plate and was dried at
room temperature. MALDI-triple quadrupole MS measurements
were carried out at the dept. Neurology (Erasmus MC,
Rotterdam, the Netherlands).
HPLC-UV
Lopinavir and ritonavir concentrations in plasma were
determined using a validated HPLC-UV assay as described
previously [24]. HPLC-UV measurements were performed at
the dept. Clinical Pharmacy (UMC St. Radboud, Nijmegen, the
Netherlands). For the cross-validation, the samples were prepared
independently at the two sites, and analytes and internal standards
were not exchanged between the laboratories.
Patients and sampling
HIV-1 infected children included were from the outpatient
clinic of the Erasmus MC – Sophia, Rotterdam, the Netherlands.
Venous blood was drawn at a single time point during their
routine 3-month visits at the outpatient clinic. For quantitation of
lopinavir and ritonavir in plasma, blood was collected in lithium-
heparinised tubes. Single time point plasma concentrations of
lopinavir and ritonavir were determined during each visit at our
outpatient clinic, which is part of the routine clinical care (HPLC-
UV assay, dept Clinical Pharmacy UMC St. Radboud). Samples
used for cross validation were obtained from an HIV-1 infected
child who was admitted to our paediatric ward for determination
of lopinavir and ritonavir plasma concentrations over a 12 hour
time interval after observed intake of Kaletra. For quantitation of
lopinavir and ritonavir in PBMCs, venous blood was collected in
one or two Vacutainer CPT tubes (BD, NJ, USA). The Vacutainer
CPT tubes were transported to the laboratory immediately after
drawing of the blood sample.
For PBMCs treated with red blood cell lysis buffer (see below),
PBMCs (and plasma) were collected from 16 HIV-1 infected
children during one outpatient visit, and from one HIV-1 infected
child PBMCs (and plasma) were collected during two consecutive
visits at our outpatient clinic, i.e. a total of 17 PBMC samples were
treated with red blood cell lysis buffer. Median age of the patients
was 10.5 years old (25th – 75th percentile: 8.6 – 13.7). Eight
patients were male, and nine were female. Fifteen patients received
Kaletra + lamivudine + abacavir once daily and one patient
received Kaletra + emtricitabine + tenofovir once daily. Samples
were drawn at a median of 16 hours after Kaletra intake (25th –
75th percentile: 14.8 – 17.3). PBMC processing time (time between
drawing of the blood sample and storage at -80uC) was 80 minutes
(25th – 75th percentile: 75 – 90). For PBMCs not treated with red
blood cell lysis buffer, PBMCs (and plasma) were collected from
eight HIV-1 infected children during one outpatient clinic visit, i.e.
eight PBMC samples were not treated with red blood cell lysis
buffer. Median age of the patients was 10.5 years old (25th – 75th
percentile: 8.9 – 13.0). Three patients were male, and five were
female. Seven patients received Kaletra + lamivudine + abacavir
once daily and one patient received Kaletra + emtricitabine +
tenofovir once daily. Samples were drawn at a median of
14.5 hours after Kaletra intake (25th – 75th percentile: 13.3 –
16.5). PBMC processing time (time between drawing of the blood
sample and storage at 280uC) was 78 minutes (25th – 75th
percentile: 72 – 83).
Isolation of PBMCs from HIV infected patients
The Vacutainer CPT tubes were processed immediately upon
arrival in the laboratory. Tubes were centrifuged at 1750 g, brake
5, at room temperature for 15 minutes. The plasma layer
containing the PBMCs was transferred to 15 mL polypropylene
tubes (Falcon conical tubes; BD, NJ, USA) and ice-cold PBS was
added until a volume of 12 mL was reached. Samples were
centrifuged at 650 g with brake 9, at 4uC for 6 minutes. The
supernatant was discarded and the cell pellet was loosened by
gently ticking against the tube. Two mL of red blood cell lysis
buffer (room temperature) was added, and cells were incubated for
1–2 minutes while gently swirling the cells. Ice-cold PBS was
added until a volume of 12 mL was reached. For part of the
samples, the red blood cell lysis buffer was not used. In that case,
ice-cold PBS was directly added after loosening of the cell pellet.
Samples were centrifuged at 350 g with brake 9, at 4uC for 6
minutes. The supernatant was discarded and ice-cold PBS was
added until a volume of 12 mL was reached. Samples were
centrifuged at 350 g, brake 9, at 4uC for 6 minutes. For part of the
samples, 1 mL of supernatant was collected to investigate the
amount of drugs present in the final wash step, and the remaining
supernatants were discarded. We estimated that ,20 mL washing
fluid remained on top of the cell pellet after discarding the
supernatant. Cells were then suspended in a small volume of ice-
cold PBS, typically 200 – 400 mL depending on the estimated
amount of cells isolated. Nucleated cells were counted by trypan
blue dye exclusion and/or Tu¨rks using a Burker-Tu¨rk counting
chamber and a light microscope. Cell viability was over 95%.
Subsequently, ice-cold PBS was added until a concentration was
reached of one million PBMC per 100 mL PBS. Cell suspensions
were aliquoted as one million nucleated cells, i.e. PBMCs,
in 100 mL per 1.5 mL polypropylene tube, and were stored at
– 80uC.
Isolation of PBMC from buffy coat
For preparation of the calibrators, quality controls, blanks, and
zeros, PBMCs were isolated from a buffy coat (Sanquin,
Rotterdam, the Netherlands) using a standard Ficoll density
gradient. Nucleated cells were counted by trypan blue dye
exclusion using a Burker-Tu¨rk cell chamber and a light
microscope. Cell viability was over 95%. PBMCs were aliquoted
in 1.5 mL polypropylene tubes at a concentration of 10 million
cells in 500 mL PBS, and were subsequently stored at – 80uC.
Preparation of PBMC from HIV infected patients
PBMC samples were thawed to room temperature. Subse-
quently, 300 mL MeOH was added and 20 mL internal standard
(2 mM nelfinavir in MeOH). Samples were extracted for at least
one hour at 5uC. Samples were then sonicated at 70% amplitude
at 27uC for 10 seconds (Branson Digital Sonifier), and then
further extracted at 5uC overnight. The next day, samples were
centrifuged at 14,000 rpm at room temperature for 5 minutes,
supernatants were collected and transferred to a 96-wells
polypropylene plate. Nanopure water (800 mL) was added to each
sample and the samples were processed using a 96-wells solid
phase extraction (SPE) plate (Oasis HLB melution plate, Waters
Corporation, Milford, Massachusetts, USA). SPE wells were
conditioned with 200 mL MeOH, and equilibrated with 200 mL
nanopure water. Subsequently, the samples were loaded on to the
SPE wells (600 mL twice). The wells were washed twice with
600 mL MeOH/nanopure water (1:3, v/v), and the samples were
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eluted from SPE wells with 50 mL MeOH twice. The eluates were
collected in a polypropylene microtiter plate, and dried using a
SpeedVac (,1 hour using a heated mantle at 45uC). Samples were
then reconstituted in 10 mL matrix solution, 0.75 mL matrix/
sample mixture was deposited on three positions on the target
plate and dried at room temperature.
Preparation of PBMCs obtained from buffy coat
PBMC samples (10 million PBMC in 500 mL PBS per vial) were
thawed to room temperature, and 500 mL MeOH was added to
each vial. Subsequently, samples were spiked with 20 mL internal
standard (20 mM nelfinavir) and 20 mL analytes (Kaletra oral
solution diluted in MeOH). Samples were then sonicated at 70%
amplitude at 27uC for 10 seconds (Branson Digital Sonifier). The
equivalent of one million PBMCs (104 mL) was transferred to a
clean 1.5 mL polypropylene vial and 300 mL MeOH/PBS (5/1,
v/v) was added. Samples were extracted at 5uC overnight and
further processed as described above for the PBMC samples of
HIV infected patients.
Safety statement
Blood samples of HIV infected patients were transported in
closed containers and were processed in a biosafety level 2
laboratory. Extraction of the plasma and PBMC samples in
methanol for one hour inactivated infectious HIV as reported
previously [24–26]. Further sample preparation steps and
measurements were performed under less stringent safety
conditions.
Results
Plasma
First we tested the MALDI-triple quadrupole MS approach on
plasma samples, which is currently the standard type of sample for
drug monitoring.
Protein precipitation of plasma with methanol provided
sufficiently clean extracts for precise, accurate, and sensitive
quantitative analysis of HIV protease inhibitors by MALDI-triple
quadrupole MS (see below), and further preparation of the plasma
samples with solid phase extraction was therefore not needed.
Simultaneous quantification of lopinavir and ritonavir was
achieved using nelfinavir as internal standard, and SRMs were
performed on the sodium adducts of these drugs. For these
analyses, sodium iodide (NaI) was added to the matrix solution to
increase the intensity of the sodium adducts of the drugs. For the
simultaneous quantification of saquinavir, indinavir, and nelfina-
vir, we used methotrexate as internal standard and SRMs were
performed on the protonated forms of the drugs (for instrument
settings see Table 1). The lower limits of quantification (LLOQ)
obtained in plasma were 167 nM for lopinavir, 14.5 nM for
ritonavir, 16 nM for nelfinavir, 16 nM for indinavir, and 3.2 nM
for saquinavir, and the precisions and accuracies were within the
criteria set by the FDA for bioanalysis [27]. Co-medication did not
affect the performance of the assays, as shown by spiking of the
quality control samples with an additional ten drugs at a plasma
concentration of 10 mM each (see Table S1). The MALDI-triple
quadrupole MS assay was used to determine a pharmacokinetic
curve of lopinavir and ritonavir in an HIV-1 infected child
receiving Kaletra and two nucleoside reverse transcriptase
inhibitors (NRTI) twice daily per os. Samples were also measured
using a validated HPLC-UV assay (International Quality Control
Program for Therapeutic Drug Monitoring in HIV infection,
Department of Clinical Pharmacy, University Medical Center
Nijmegen, the Netherlands) [24]. The two assays yielded similar
results. For the MALDI-triple quadrupole MS assay, spiking of the
patient’s samples with an additional ten drugs (10 mM each) did
not affect the results (see Figure 1 and Table S2).
PBMCs
We developed a MALDI-triple quadrupole MS assay for
simultaneous quantification of lopinavir and ritonavir in one
million peripheral blood mononuclear cells (PBMC). The LLOQ
was 834 nM for lopinavir and 73 nM for ritonavir, and the
precisions and accuracies were within the criteria set by the FDA
for bioanalysis (see Table S3). Storage of the sample on the target
plate in a closed container at ambient conditions for up to one
month analyzed did not affect the precisions, accuracies, or
LLOQs (data not shown).
The intracellular concentrations were determined by taking into
account that one averaged PBMC has an intracellular volume of
4610213 L. To assess the effect of solid phase extraction on the
precisions and accuracies, we processed one set of plasma samples
that were used for cross-validation with HPLC-UV using the solid
phase extraction protocol for PBMCs, and we found that this step
did not affect the precisions or the accuracies for lopinavir and
ritonavir (data not shown). Shown in Table 2 are the precisions for
biological replicates, i.e. analysis of multiple PBMC aliquots from
HIV infected children (three aliquots per child).
Assessment of the purity of the cells aliquoted showed that
4.66105 erythrocytes (sd 3.46105, n= 5) were present per aliquot
of 16106 PBMC. Treatment of the cells isolated with red blood
cell lysis buffer (2 minutes, room temperature) during the washing
procedure resulted in .2 Log reduction in the number of
erythrocytes per million PBMC (mean 3.86103 erythrocytes, sd
5.96103, n = 5). For eight HIV-1 infected children receiving
Kaletra and 2 NRTIs once daily, we determined the concentra-
tions of lopinavir and ritonavir in the final wash step and found
that these constitute less than 4.5% (lopinavir) and less than 8.7%
(ritonavir) of the amount measured in one aliquot of one million
PBMC.
Application
The MALDI-triple quadrupole MS assay was used to determine
the intracellular concentrations of lopinavir and ritonavir in
PBMC obtained from HIV-1 infected children receiving Kaletra
(lopinavir + ritonavir) and two NRTIs once daily. Part of the
samples was processed with red blood cell lysis buffer and part
without to further investigate the effect of using this buffer on the
concentrations determined. Plasma concentrations of lopinavir
and ritonavir were determined by HPLC-UV, which is part of the
routine clinical care in our setting. Blood samples were drawn at a
single time point after medication intake. Plasma and intracellular
concentrations of lopinavir and ritonavir are shown in Table 3,
and the correlations are shown in Table 4.
Discussion
Liquid chromatography (LC) – based assays are widely used to
determine drug concentrations in human samples, in particular
assays that combine LC with UV-light detection or with detection
by electrospray ionization (ESI) mass spectrometry (MS). Of these
two platforms, LC-ESI-MS provides in general better sensitivities,
a higher selectivity and shorter analysis times than LC-UV. Still,
high throughput quantitative analysis is difficult to achieve using
LC-based assays, because the most time-consuming part of the
analysis, i.e. the LC-step, takes at least several minutes per sample.
The LC-step is not necessarily needed for sensitive quantitative
analysis of drugs in biological samples using MALDI mass
Antiviral Drug Levels in Cells
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spectrometry, because MALDI suffers less from ion suppression
than ESI [23,28]. The analysis time using MALDI-based assays is
considerably shorter than using LC-based assays; in this case
samples were measured at a speed of 13.5 seconds per sample
(triplicate analysis), which is approximately 25 – 100 times faster
than the LC-based approaches [2,29–31]. The LLOQs in PBMCs
for our MALDI-MS assay were 25 femtomole per spot for
lopinavir and 2.2 femtomole per spot for ritonavir, which is
comparable to the LLOQs in PBMCs of 6 femtomole on column
for lopinavir and 5 femtomole on column for ritonavir for the LC-
ESI-MS assay described by Colombo et al. [2]. Runtime of that
assay was 20 minutes, and accuracies were still below the
recommended 15% when a variable amount of input material,
i.e. between 1.46106 PBMCs and 9.66106 PBMCs, was used for
the assay. Pe`lerin et al. described an LC-ESI-MS assay with an
LLOQ of 70 femtomole per mL intracellular volume for ritonavir
and 80 femtomole per mL intracellular volume for lopinavir [30].
The amount of PBMCs isolated from 7 mL blood was used as
input material for the assay. Runtime of the assay was 20 minutes.
Ter Heine et al. described an LC-ESI-MS assay with LLOQ of 1.9
femtomole/36106 PBMCs for lopinavir and an LLOQ of 1.7
femtomole/36106 PBMCs for ritonavir [31]. Runtime of the assay
Table 2. Repeat analysis of PBMC aliquots obtained from HIV-1 infected children.
aliquot 1 (mM) aliquot 2 (mM) aliquot 3 (mM) mean (mM) %CV
patient drug spot 1 spot 2 spot 3 spot 1 spot 2 spot 3 spot 1 spot 2 spot 3
1 LPV 2.61 2.70 2.70 2.71 2.84 2.73 2.80 3.14 2.90 2.79 5.6
2 LPV 4.66 5.34 5.01 3.97 4.22 4.01 4.48 4.00 4.88 4.51 11.1
3 LPV 2.11 2.05 2.08 2.43 2.48 2.47 2.13 2.24 2.65 2.29 9.5
1 RTV 0.299 0.279 0.322 0.290 0.278 0.277 0.340 0.313 0.309 0.301 7.3
2 RTV 0.495 0.478 0.469 0.401 0.427 0.396 0.427 0.443 0.459 0.444 7.7
3 RTV 0.336 0.351 0.346 0.336 0.347 0.359 0.375 0.354 0.369 0.352 3.8
For three HIV-1 infected children receiving Kaletra once daily, three aliquots of one million PBMC each were processed as described in the text (solid phase extraction
followed by methanol extraction, and spotting in triplicate) to determine the overall precisions (%CV) of PBMC processing and sample measurements. Shown are the
concentrations of lopinavir (LPV) and ritonavir (RTV) in mM as determined in a single spot on the target plate.
doi:10.1371/journal.pone.0011409.t002
Figure 1. Lopinavir and ritonavir concentrations in an HIV infected child determined by HPLC-UV and by MALDI-triple quadrupole
MS. Pharmacokinetic curve of lopinavir and ritonavir in one HIV infected child determined by HPLC-UV (triangles for lopinavir and crosses for
ritonavir), MALDI-triple quadrupole MS (diamonds for lopinavir and circles for ritonavir), and MALDI-triple quadrupole MS when ten additional drugs
(10 mM per drug) were spiked to the patient’s samples (squares for lopinavir and pluses for ritonavir).
doi:10.1371/journal.pone.0011409.g001
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was 10 minutes. For clinical samples, an aliquot of 36106 PBMCs
was extracted in a volume of 200 mL, and 30 mL extract was used
for LC-ESI-MS analysis. Ehrardt et al. described an LC-ESI-MS
method with an LLOQ of 139 fmol/36106 PBMCs for ritonavir
and 159 fmol/36106 PBMCs for lopinavir [29]. Runtime of the
assay was 6 minutes. After sample preparation of 36106 PBMCs,
the dried extracts were reconstituted in 200 mL LC mobile phase
and 40 mL were used for LC-ESI-MS measurements. LC-ESI-MS
methods published thusfar have not been validated specifically for
quantification of lopinavir and ritonavir in 16106 PBMCs. Yet,
the sensitivities of the assays described in literature are likely to be
sufficient for that purpose. In this study, we specifically validated
our assay for quantification of lopinavir and ritonavir in 16106
PBMCs, because of our interest in pharmacokinetics of antitre-
troviral drugs in children. For the same reason, we specifically
validated our assay for quantification of HIV protease inhibitors in
10 mL plasma.
We used the Selected Reaction Monitoring (SRM) mode of the
MALDI – triple quadrupole mass spectrometer to circumvent
background signals derived from the biological sample and from
the matrix. In the SRM-mode of a triple quadrupole mass
analyzer, only ions with masses corresponding to the mass of the
compound of interest are able to pass the first quadrupole, in the
second quadrupole the ions collide with a gas resulting in
fragmentation, and in the third quadrupole only the fragment
ions are able to pass whose masses correspond with the mass of a
specific fragment of the drug of interest. The fragmentation
pattern of an ion is highly structure specific, and isobaric ions
derived from the matrix or from the biological sample are not able
to pass through the triple quadrupole mass analyzer and are thus
not detected. In addition, the SRM-mode enhances the sensitivity
of the measurements and extends the linear dynamic range [17].
We have previously shown that MALDI-triple quadrupole is a
suitable technique to quantify HIV protease inhibitors in PBMC
extracts [20]. In this study, we show clinical application as well as
quantitative analysis of HIV protease inhibitors in plasma
including a cross-validation, and we used a different matrix, i.e.
a-cyano-4-hydroxycinnamic acid, which resulted in better preci-
sions and higher sensitivities. Furthermore, we show that the
MALDI-triple quadrupole MS approach allows for multi-target
quantification using a chemical analogue as internal standard, and
that samples co-crystallized with matrix are stable at ambient
conditions for up to a month. Thus, samples can be stored and
measured multiple times with the same or a different type of
MALDI mass spectrometer. In this study, we used HIV protease
inhibitors as model compounds, but the approach is also
applicable to other drugs. For example, we were able to quantify
methotrexate down to 5 nM in plasma (data not shown).
The sample preparation techniques used prior to MALDI-triple
quadrupole MS analysis allow for fast and automated processing of
large numbers of samples, e.g. in 96-wells plate format [23].
Normally, these sample preparation techniques are also used for
subsequent analysis by LC-based assays. Plasma and cells were
extracted in methanol, which simultaneously inactivates infectious
HIV [25,26]. For plasma, no further sample preparation steps
were needed, i.e. the lysates were mixed with matrix solution and
deposited on a target plate. Drying of the plasma lysates after
protein precipitation and subsequent reconstitution in a small
Table 3. Plasma and intracellular concentrations of lopinavir
and ritonavir in HIV-1 infected children.
RBCLB+ (n = 17) RBCLB- (n =8) p-value
mM lopinavir plasma 16.1 (9.8 – 21.2) 15.7 (10.3 – 19.7) 0.930
mM lopinavir PBMC 4.4 (2.8 – 6.0) 3.3 (3.0 – 7.1) 0.975
PBMC/plasma ratio
lopinavir
0.34 (0.19 – 0.39) 0.26 (0.18 – 0.36) 0.634
mM ritonavir plasma 0.62 (0.36 – 1.17) 0.72 (0.42 – 0.90) 0.884
mM ritonavir PBMC 0.32 (0.28 – 0.35) 0.89 (0.49 – 1.23) 0.001
PBMC/plasma ratio
ritonavir
0.46 (0.31 – 0.70) 1.53 (0.85 – 2.36) 0.004
Hours after intake 16.0 (14.8 – 17.3) 14.5 (13.3 – 16.5) 0.243
Age 10.5 (8.6 – 13.7) 10.5 (8.9 – 13.0) 0.861
PBMC processing time
(minutes)
80 (75 – 90) 78 (72 – 83) 0.188
Values between brackets are expressed as medians (25th percentile – 75th
percentile). P values were determined using a Mann Whitney U test. All patients
administered Kaletra (lopinavir + ritonavir) +2 NRTIs once daily.
RBCLB+= PBMCs treated with red blood cell lysis buffer. RBCLB- = PBMCs not
treated with red blood cell lysis buffer. The RBCLB+ group consisted of 16 HIV-1
infected children. For one child, concentrations were determined during two
separate visits at the outpatient clinic. RBCLB- group consisted of 8 HIV-1
infected children. Three children were included in both the RBCLB+ group and
RBCLB- group as for these patients samples were processed with and without
RBCLB. Plasma concentrations were determined by HPLC-UV and intracellular
concentrations by MALDI-triple quadrupole MS. For one patient in the RBCLB-
group, intracellular concentration of lopinavir was below the LLOQ while the
intracellular concentration of ritonavir was above the LLOQ. Hours after intake
= time difference in hours between medication intake and drawing of the
blood sample. PBMC processing time = time difference between drawing of
the blood sample and aliquoting of the PBMC.
doi:10.1371/journal.pone.0011409.t003
Table 4. Correlations between plasma and intracellular levels, and correlations between the concentrations of the two drugs in
HIV-1 infected children.
RBCLB+ (n = 17) RBCLB- (n =8)
lopinavir and ritonavir in plasma 0.973 (0.01) 0.952 (0.01)
lopinavir and ritonavir in PBMC 0.613 (0.01) 0.757 (0.05)
lopinavir in plasma and in PBMC 0.475 (NS) 0.613 (NS)
Ritonavir in plasma and in PBMC 0.510 (0.05) 0.500 (NS)
PBMC/plasma ratio lopinavir and PBMC/plasma ratio ritonavir 0.604 (0.05) 0.464 (NS)
lopinavir in plasma and in PBMC 0.531 (0.01) (RBCLB+ and RBCLB- combined)
lopinavir and ritonavir in plasma 0.965 (0.01) (RBCLB+ and RBCLB- combined)
Correlations were calculated using a Spearman correlation. Significance levels are reported between brackets. NS = not significant.
doi:10.1371/journal.pone.0011409.t004
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volume of matrix solution resulted in poor crystallization of the
samples and severe loss in sensitivity, which is in agreement with
two previous reports [16,22]. In our approach, the plasma samples
are simply diluted 30 times, which results in good crystallization
and highly sensitive measurements. For PBMC samples, we found
that this methanol dilution step did not result in the sensitivity
needed for intracellular quantitative analysis of HIV protease
inhibitors in clinical samples, and therefore samples were further
processed with solid phase extraction.
The MALDI-triple quadrupole MS assay was used to
investigate the intracellular concentrations of lopinavir and
ritonavir in relation to their plasma concentrations in HIV-1
infected children receiving Kaletra, a co-formulation of the HIV
protease inhibitors lopinavir and ritonavir (4:1, w/w), once daily.
Both drugs are metabolized in the liver by CYP3A4 isoenzymes.
Ritonavir inhibits the CYP3A4-mediated metabolism, thereby
enhancing the pharmacokinetic properties of lopinavir [32]. This
is in agreement with the strong correlation (r=0.97, p = 0.01) that
we found between the plasma concentrations of lopinavir and the
plasma concentrations of ritonavir in HIV-1 infected children.
Ribera et al. also found a correlation between the plasma AUC of
lopinavir and ritonavir in HIV-1 infected adults, although this
correlation was less pronounced (r = 0.63, p,0.001) [33].
Whether lopinavir and ritonavir enter the cellular compartment
in blood by passive diffusion, active transport, or a combination of
both, is currently unknown. Passive diffusion is likely to occur as
lopinavir and ritonavir are both lipophilic drugs with an octanol/
saline partition coefficient of 214 and 22.2, respectively, and are
thus able to cross the plasma membrane and enter the cells. Active
transport into cells has not been reported yet. On the other hand,
lopinavir and ritonavir are substrates for drug efflux pumps,
although no correlation has been found between drug efflux
pumps and intracellular concentrations of HIV protease inhibitors
in HIV infected patients [5,10]. It should be noted that only
unbound non-ionized drugs can cross the cell membrane by
passive diffusion. In vivo, the unbound concentrations of lopinavir
and ritonavir are only 1–2% of the total amount in plasma. In
vitro studies have already shown that the high protein binding
significantly affects the accumulation of protease inhibitors
[34,35]. It is expected that lopinavir and ritonavir are also highly
bound to proteins within cells. To which proteins and to what
extent is currently unknown.
Disposition studies of lopinavir and ritonavir in rats showed that
both HIV protease inhibitors penetrate poorly into the cellular
fraction of blood. Literature indicates a whole blood/plasma ratio
of 0.5 for lopinavir and a whole blood/plasma ratio of 0.26 to 0.68
for ritonavir [36,37]. Koal et al. also reported lower concentrations
of HIV protease inhibitors in whole blood compared to plasma in
HIV infected patients [38]. This shows that lopinavir and ritonavir
penetrate poorly into the cellular fraction of blood. It should be
noted that the cellular fraction of whole blood consists for .99%
of erythrocytes, and that differences may exist between penetration
in erythrocytes and in PBMC.
Accumulation of lopinavir [1,4] and ritonavir [4] in PBMC has
been reported in HIV-1 infected adults receiving Kaletra BID:
Breilh et al. reported a PBMC/plasma ratio of lopinavir of 3.2
(month 1) and 2.4 (month 6) in patients who responded to therapy,
and 2.3 (month 1) and 1.4 (month 6) in patients who failed on
therapy [1]. Ritonavir concentrations were not determined in this
study. Crommentuyn et al. reported a PBMC/plasma ratio of 1.18
for lopinavir and 4.59 for ritonavir in HIV-1 infected adults
receiving Kaletra BID [4]. Ritonavir accumulation was also
reported by Khoo et al. They observed a PBMC/plasma ratio of 1
when ritonavir is administered as sole protease inhibitor, 1.25
using ritonavir-boosted saquinavir, and 1.8 using ritonavir-boosted
indinavir [39]. On the other hand, Colombo et al. reported a
PBMC/plasma ratio of 0.55 for lopinavir in HIV infected adults
[2,3]. Ehrhardt et al. showed in one healthy volunteer that, after a
single dose of Kaletra, lopinavir concentrations were lower in
PBMC than in plasma, but ritonavir concentrations were higher in
PBMC than in plasma [29].
In this study, we found lower lopinavir concentrations in PBMC
than in plasma in HIV-1 infected children receiving Kaletra once
daily. For ritonavir, accumulation in PBMC was highly dependent
on the sample preparation used. When erythrocytes were removed
by RBCLB no accumulation was found, while accumulation was
found when not using RBCLB. This shows that sample
preparation can have a major influence on the concentrations
measured. This step was included in the sample preparation
protocol because of the erythrocytes present in cell suspensions
after Ficoll density gradient centrifugation and subsequent
thorough washing of the cells. Although cells were incubated for
only two minutes in this buffer, we cannot exclude efflux of
ritonavir because this incubation occurred at room temperature.
However, this does not explain the lower PBMC concentrations
compared to plasma for lopinavir as there were no significant
differences in the PBMC/plasma ratio when PBMC were
prepared with RBCLB or without RBCLB.
In our opinion, the higher PBMC/plasma ratios when RBCLB
is not used is not due to high intracellular concentrations of
ritonavir in erythrocytes. Previous studies have already shown
poor penetration of this drug in blood cells (see above). In addition,
when RBCLB was not used, the erythrocyte/PBMC ratio in the
cell preparation was ,1:2 (count/count), and the intracellular
volume of an erythrocyte is lower (,80 fL) compared to that of an
average PBMC (,400 fL). An explanation might be that, due to
erythrocyte lysis, proteins are released into the lysis buffer and that
ritonavir bound to proteins on the outside of the plasma
membrane now bind to the erythrocyte-derived proteins in the
buffer. On the other hand, this effect was not observed for
lopinavir. Ritonavir but also lopinavir are highly bound in plasma
to albumin and a1-acid glycoprotein [32]. In vitro studies have
already shown that higher protein concentrations in cell
cultures result in significantly lower intracellular concentrations
[34,35].
We found a correlation between the intracellular concentrations
of lopinavir and the intracellular concentrations of ritonavir
(r=0.61, p= 0.01 and r=0.76, p = 0.05; RBCLB+ and RBCLB-,
respectively). This is in agreement with previous reports on
ritonavir-boosted saquinavir and ritonavir-boosted indinavir
[5,39,40]. To our best knowledge this is the first time such
correlation is shown for Kaletra. We found that the correlation
between the plasma concentrations and intracellular concentra-
tions of lopinavir (r=0.53, p = 0.01) or ritonavir (r=0.51,
p = 0.05 and r=0.5, NS; RBCLB+ and RBCLB- respectively)
were less pronounced. Breilh et al. showed for HIV-1 infected
adults receiving Kaletra BID that the plasma concentrations of
lopinavir correlated with the intracellular concentrations of
lopinavir after one month of treatment (r2 = 0.72, p,1026). Yet,
this correlation was not found after six months of treatment
(r2 = 0.17, p= 0.3) [1]. For ritonavir, this correlation was not
assessed. For ritonavir-boosted saquinavir, the plasma concentra-
tions of ritonavir correlated poorly to the intracellular concentra-
tions: r2 = 0.33; p = 0.053 and r2 = 0.31, p = 0.06) [5,40]. Above
shows that lopinavir levels and ritonavir levels correlate to each
other within the same compartment, i.e. plasma or PBMC, but
also that for each drug the correlation between these compart-
ments is poor.
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In conclusion, we have developed a novel assay for the fast and
sensitive quantification of compounds that can be applied to
monitor drugs in plasma and intracellularly in treatment of various
illnesses including antiviral treatment.
Supporting Information
Table S1 Quantitative analysis of HIV protease inhibitors in
plasma. The first column shows the specific drug and the second
column shows the concentration of the drug spiked in plasma in
mM. The third column shows the actual amount of drug in
femtomoles (fmol) in a single spot on the target plate. The fourth
column shows the accuracies, expressed as % deviation, for
samples used to construct the calibration curve (calibrators), and
the fifth column show the accuracies for samples used to test the
validity of the calibration curve (quality controls). Precisions,
expressed as %CV, are reported between brackets (n = 9 spots on
the target plate). For the analysis of lopinavir and ritonavir, quality
controls were spiked with carbamazepine, metoprolol, metroni-
dazol, amoxicillin, piroxicam, nevirapine, saquinavir, efavirenz,
indinavir, and tipranavir at a plasma concentration of 10 mM
each. For analysis of nelfinavir, saquinavir, and indinavir, quality
controls were spiked with efavirenz, tipranavir, lopinavir, ritona-
vir, carbamazepine, metoprolol, metronidazol, amoxicillin, priox-
icam, and nevirapine at a plasma concentration of 10 mM each.
These drugs were not added to the calibrators. The calibrators
were prepared in plasma from a different healthy donor than the
quality controls were.
Found at: doi:10.1371/journal.pone.0011409.s001 (0.06 MB
DOC)
Table S2 Lopinavir and ritonavir concentrations in plasma in an
HIV-1 infected child. The first column shows the time points in
hours at which blood samples were collected from one HIV-1
infected child after observed intake of Kaletra. The second column
shows the components of Kaletra, i.e. lopinavir and ritonavir. The
third column shows the concentration of the compounds in mM
determined by HPLC-UV. The fourth and fifth columns show the
concentration of the compounds in mM determined by MALDI-
triple quadrupole MS. Three technical replicates were measured
for each sample, i.e. three spots on the target plate. The precisions
(%CV) are reported between brackets. The sixth and seventh
columns show the deviations in percentage between the concen-
tration of the compounds determined by MALDI-triple quadru-
pole MS and by HPLC-UV. For the MALDI-triple quadrupole
MS analyses, one set of samples was spiked with an additional ten
drugs (‘‘drugs added’’) and one set was not (‘‘no drugs added’’).
The additional ten drugs spiked were carbamazepine, metoprolol,
metronidazol, amoxicillin, piroxicam, nevirapine, saquinavir,
efavirenz, indinavir, and tipranavir at a plasma concentration of
10 mM each.
Found at: doi:10.1371/journal.pone.0011409.s002 (0.05 MB
DOC)
Table S3 Quantitative analysis of lopinavir and ritonavir in one
million PBMC. The regression coefficient were .0.998.
Found at: doi:10.1371/journal.pone.0011409.s003 (0.04 MB
DOC)
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